Zobrazeno 1 - 10
of 416
pro vyhledávání: '"P. Vuagnat"'
Autor:
C. Helissey, C. Parnot, C. Rivière, C. Duverger, A. Schernberg, S. Becherirat, H. Picchi, A. Le Roy, P. Vuagnat, R. Pristavu, H. Vanquaethem, L. Brureau
Publikováno v:
Frontiers in Digital Health, Vol 5 (2023)
Research aim and purposeThe benefits of Electronic Patient -Reported Outcomes (e-PRO) for telemonitoring are well established, allowing early detection of illnesses and continuous monitoring of patients. The primary objective of the PROTECTY study wa
Externí odkaz:
https://doaj.org/article/11990258219a4d839de2c10ec42073d2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NC
Externí odkaz:
https://doaj.org/article/cc022ab82e6e4fd69d684a17c4dfa3ff
Autor:
Marc-Antoine Sanchez, Albert Vuagnat, Olivier Grimaud, Emmanuelle Leray, Jean-Marc Philippe, François-Xavier Lescure, Mathieu Boutonnet, Hélène Coignard, Agnès Ricard Hibon, Stephane Sanchez, Julien Pottecher
Publikováno v:
Annals of Intensive Care, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Background The first wave of the COVID-19 pandemic confronted healthcare systems around the world with unprecedented organizational challenges, particularly regarding the availability of intensive care unit (ICU) beds. One strategy implement
Externí odkaz:
https://doaj.org/article/636771b4dde84c0aab47bdedf5a32de9
Autor:
Younes Belkouchi, Laetitia Nebot-Bral, Littisha Lawrance, Michele Kind, Clémence David, Samy Ammari, Paul-Henry Cournède, Hugues Talbot, Perrine Vuagnat, Cristina Smolenschi, Patricia L. Kannouche, Nathalie Chaput, Nathalie Lassau, Antoine Hollebecque
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAnti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate is highly heterogeneous across MMRD tumors. The objective of the study is to find a score
Externí odkaz:
https://doaj.org/article/fae99fd4b90a457bb087c481b50e2a46
Autor:
Jean-Yves Scoazec, Antoine Hollebecque, Aurélien Marabelle, Alexandra Leary, Lydie Cassard, Nathalie Chaput, Cristina Smolenschi, Perrine Vuagnat, Jean-Mehdi Jouniaux, Laetitia Nebot-Bral, Andrey A Yurchenko, Louise de Forceville, Mathieu Danjou, Reginaldo C A Rosa, Caroline Pouvelle, Said Aoufouchi, Emeline Colomba, Sergey Nikolaev, Patricia Kannouche
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. However, the responsiveness of MMRD cancers to αPD-1 therapy is highly
Externí odkaz:
https://doaj.org/article/e34026e4687a48cba574cb8fd575cd1c
Autor:
Marion Alhenc-Gelas, Luc Cabel, Frederique Berger, Suzette Delaloge, Jean-Sebastien Frenel, Christelle Levy, Nelly Firmin, Sylvain Ladoire, Isabelle Desmoulins, Pierre-Etienne Heudel, Florence Dalenc, Delphine Loirat, Coraline Dubot, Perrine Vuagnat, Elise Deluche, Meriem Mokdad-Adi, Anne Patsouris, Josselin Annic, Lounes Djerroudi, Marion Lavigne, Jean-Yves Pierga, Paul Coppo, Francois-Clement Bidard
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Cancer-related microangiopathic haemolytic anaemia (MAHA) is a rare but life-threatening paraneoplastic syndrome. Only single cases or small series have been reported to date. We set up a retrospective multicentre study focusing o
Externí odkaz:
https://doaj.org/article/f7239abd3511401b9773a7aef4c9d1ce
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Perrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, Clémence Basse, Sarah Diakite, Aurélien Noret, Audrey Bellesoeur, Vincent Servois, Delphine Hequet, Enora Laas, Youlia Kirova, Luc Cabel, Jean-Yves Pierga, Institut Curie Breast Cancer and COVID Group, Laurence Bozec, Xavier Paoletti, Paul Cottu, François-Clément Bidard
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals
Externí odkaz:
https://doaj.org/article/3ffdcc67e1c249f98223450d86a4e01c
Autor:
Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard
Publikováno v:
Cancer Medicine, Vol 9, Iss 8, Pp 2643-2652 (2020)
Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PS
Externí odkaz:
https://doaj.org/article/a4e7a1041c934bc3942c24fc39614624